medicare semaglutide coverage covers GLP-1s for $50/month starting July 2026 Semaglutide coverage for weight loss

August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone

If youre experiencing more severe hair loss, a dermatologist can guide you through appropriate treatments

Tirzepatide is a synthetic twincretin peptide that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

It reflects a rapid reduction in metabolic spillover , improved insulin dynamics, and reduced liver fat export